Breaking News

Shares rise after Cadila Healthcare gets USFDA approval for Mesalamine 

The pharmaceutical giant Zydus Cadila told that the US Food and Drug Administration known as USFDA have given approval to market Mesalamine Delayed-Release tablets USP in the USA market.

Once the Zydus Cadila shared the news, the Cadila share has encountered a wide jump in its share. The company share saw over 10% vertically increase.

Today morning around 10 AM the share goes up to the level of Rs. 534 which is about 10 % jump.

To file an abridged New Drug Application for a generic form of Lialda, Zydus Cadila was the first pharmaceutical company.  

The company will be manufactured the drug at Moraiya plant located at Ahmedabad.

The company told in a press release that Lialda is used for the treatment of ulcerative colitis. Almost 700,000 lakh people get affected by this disease in the United States.

About Admin


Comments are closed.

Scroll To Top